

BLA 761345/S-002

## SUPPLEMENT APPROVAL

Pfizer Inc  
Attention: Robert Schaum, Ph.D.  
Director, Global Regulatory Affairs  
445 Eastern Point Road  
Groton, CT 06340

Dear Dr. Schaum:

Please refer to your supplemental biologics license application (sBLA) dated and received July 18, 2024, and your amendments, submitted under section 351(a) of the Public Health Service Act for Elrexfio (elranatamab-bcmm) injection.

This Changes Being Effected sBLA provides for proposed modifications to the approved Elrexfio risk evaluation and mitigation strategy (REMS).

We have completed our review of this supplemental application, as amended. It is approved effective on the date of this letter.

### **RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS**

The REMS for Elrexfio (elranatamab-bcmm) was originally approved on August 14, 2023, and the most recent REMS modification was approved on December 13, 2023. The REMS consists of a communication plan, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

Your proposed modifications to the REMS consist of incorporation of language to advise the stakeholders that their information will be listed on a stakeholder locator tool in the REMS Prescriber Enrollment and Pharmacy and Healthcare Setting Enrollment forms, adding a Certified Participant Locator tool on the public website to help patients find prescribers and healthcare facilities that have certified in the REMS, removing the statement “e-signature functionality will be available within 30 days of approval of ELREXFIO REMS” from the Prescriber Enrollment and Pharmacy and Healthcare Setting Enrollment forms on the public website, and updating footer copyright dates from 2023 to 2024.

Your proposed modified REMS, submitted on July 18, 2024, amended and appended to this letter, is approved.

The timetable for submission of assessments of the REMS remains the same as that approved on August 14, 2023.

There are no changes to the REMS assessment plan described in our August 14, 2023, letter.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use, as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication.
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS.
- c) *If the new indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of that last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing REMS modifications,* provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted.

Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**BLA 761345 REMS ASSESSMENT METHODOLOGY**

(insert concise description of content in bold capital letters, e.g.,  
**ASSESSMENT METHODOLOGY, PROTOCOL, SURVEY METHODOLOGIES,  
AUDIT PLAN, DRUG USE STUDY**)

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**BLA 761345 REMS ASSESSMENT**

*or*

**NEW SUPPLEMENT FOR BLA 761345/ S-000  
CHANGES BEING EFFECTED IN 30 DAYS  
PROPOSED MINOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 761345/ S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED MAJOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 761345/ S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING  
CHANGES SUBMITTED IN SUPPLEMENT XXX**

*or*

**NEW SUPPLEMENT (NEW INDICATION FOR USE)  
FOR BLA 761345/ S-000  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISIONS FOR BLA 761345**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, or website screenshots are only in PDF format, they may be submitted as such, but Word format is preferred.

**SUBMISSION OF REMS DOCUMENT IN SPL FORMAT**

As soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in Structured Product Labeling (SPL) format using the FDA automated drug registration and listing system (eLIST). Content of the REMS document must be identical to the approved REMS document. The SPL will be publicly available.

Information on submitting REMS in SPL format may be found in the guidance for industry *Providing Regulatory Submission in Electronic Format – Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling*.

For more information on submitting REMS in SPL format, please email [FDAREMSwebsite@fda.hhs.gov](mailto:FDAREMSwebsite@fda.hhs.gov).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

If you have any questions, contact Jessica Kim, Safety Regulatory Project Manager, at 240-402-0883, or via email at [Jessica.Kim1@fda.hhs.gov](mailto:Jessica.Kim1@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Oladimeji Akinboro, MD, MPH  
Associate Director for Safety  
Office of Oncologic Diseases  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE:

- REMS

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

OLADIMEJI A AKINBORO  
09/10/2024 01:23:00 PM